OUR PARTNERS

Women As One and Novo Nordisk took a pivotal step toward advancing diversity, equity, and inclusion in the medical field this year with the commencement of their strategic partnership. This collaboration aims to address and rectify the stark disparities in the treatment and representation of female patients through increasing gender equity within the medical workforce. 

Novo Nordisk, a global leader in healthcare with a steadfast commitment to transforming patient care, became a Corporate Member of Women As One at the beginning of 2024. Through this partnership, both organizations are addressing disparities and paving the way for a future where all patients receive equitable and effective medical care. Through this strategic alliance, Women As One and Novo Nordisk are poised to elevate awareness and drive impactful changes in how female patients are treated and represented in medical research and practice. 

Key Initiatives and Achievements

Throughout 2024, Novo Nordisk demonstrated unwavering support for Women As One’s mission through a series of high-profile sponsorships and collaborative initiatives:

• Elite Sponsorship of RISE @ ESC Congress 2024: Novo Nordisk sponsored the RISE conference at the European Society of Cardiology (ESC) Congress. This event, held on August 29th in London, provided a platform for professional development, networking and collaboration among women in cardiology, supporting them to advance in their leadership journeys.
• Becoming a Corporate Member: Novo Nordisk has played a crucial role in supporting the organization’s efforts to promote gender equity in the medical profession through its Corporate Membership. Together, we created a customized annual program to support the organization’s gender diversity goals and enhance collective efforts to level the playing field in cardiology and beyond.
• Reception at the European Society of Cardiology: Novo Nordisk hosted an exclusive panel discussion at the ESC Congress, focusing on the importance of diversity in clinical trials, reflecting Novo Nordisk’s commitment to ensuring that clinical trial populations accurately represent the diverse populations affected by cardiovascular diseases.
• Sponsorship of the Escalator Awards Research Scholars: Novo Nordisk sponsored the 2024 Research Scholars Awards, which recognize and support emerging women researchers in cardiovascular medicine. These awards were presented to seven women physicians in partnership with the Global CVCT Forum, further highlighting the commitment to fostering the next generation of women leaders in the field.

A Vision for Equitable Access and Representation

Novo Nordisk’s vision for the future of clinical trials is one where trial populations truly reflect the diverse communities affected by cardiovascular diseases. By actively ensuring equitable access and representation in their studies, Novo Nordisk sets a new standard for inclusivity in medical research. 

“Together, we aim to pioneer programs and events that champion women physicians and foster collective efforts to level the playing field in cardiology,” said Dr. Roxana Mehran, co-founder of Women As One. “We are thrilled about the success of this groundbreaking partnership with Novo Nordisk and look forward to future collaborations.”

Looking Forward

As 2024 draws to a close, Women As One and Novo Nordisk look ahead to 2025 with optimism and determination. The partnership marks a significant milestone in achieving gender equity in the medical field. Both organizations are committed to continuing their collaborative efforts to drive positive change and create a more inclusive and equitable healthcare landscape. 

Women As One is grateful to Novo Nordisk for their collaborative partnership and shared commitments to create a better, more equitable future in healthcare. This strategic partnership underscores Novo Nordisk’s increasing support for Women As One’s mission and positions them as a steadfast advocate for diversity and innovation in the medical community.